Maze Therapeutics (Series D)
Funding Details
Awarder
Inbox
Date Award
June 8, 2025
Vertical
Biopharmaceuticals
Funding URL
View Funding Page
Funding Amount
$115,000,000
Company Info
Market
Renal, cardiovascular, and metabolic diseases
Location
South San Francisco, California, USA
Coinvestors
Frazier Life Sciences, Deep Track Capital, Janus Henderson Investors, Logos Capital, Third Rock Ventures, ARCH Venture Partners, Matrix Capital Management, GV, General Catalyst, Andreessen Horowitz (a16z), Foresite Capital, Woodline Partners LP, Casdin Capital, Piper Heartland Healthcare Capital, Moore Strategic Ventures
Company Description

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases.

Links
Back to HomeBack to Biopharmaceuticals DealsView Funding Announcement